MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Clinical trial NCT05655312 · RECRUITING

Trial details

NCT number: NCT05655312
Sponsor: Perspective Therapeutics
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Recurrent Melanoma (Skin)Metastatic Melanoma Melanoma Stage IV Melanoma Stage III

Start date: 2023-06-01
Primary completion: 2027-12-31
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.